MX2017016530A - Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1). - Google Patents

Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1).

Info

Publication number
MX2017016530A
MX2017016530A MX2017016530A MX2017016530A MX2017016530A MX 2017016530 A MX2017016530 A MX 2017016530A MX 2017016530 A MX2017016530 A MX 2017016530A MX 2017016530 A MX2017016530 A MX 2017016530A MX 2017016530 A MX2017016530 A MX 2017016530A
Authority
MX
Mexico
Prior art keywords
disorders
tetrahydrocyclo
compound1
indol
penta
Prior art date
Application number
MX2017016530A
Other languages
English (en)
Inventor
c blackburn Anthony
Karyn Rueter Jaimie
O Castro Ryan
A Hadd Mark
Ma You-An
Garrido Montalban Antonio
Alani Selvey Lee
Raj SHAKYA Sagar
Carlos Marlon
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56322311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017016530(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MX2017016530A publication Critical patent/MX2017016530A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención se refiere a, entre otras cosas, un hábito o morfología cristalina de placa libre, a procedimientos para preparar el hábito cristalino de placa libre, y a los usos del hábito cristalino de placa libre de la sal de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4 -tetrahidrociclopenta[b]indol-3-il)acético (Compuesto 1) en el tratamiento de trastornos asociados con el receptor S1P1, por ejemplo, enfermedades y trastornos mediados por linfocitos, rechazo de trasplante, enfermedades y trastornos autoinmunes, enfermedades y trastornos inflamatorios (por ejemplo, condiciones inflamatorias agudas y crónicas), cáncer, y condiciones caracterizadas por un defecto subyacente en la integridad vascular o que están asociadas con angiogénesis tal que pudieran ser patológicas (por ejemplo, como puede ocurrir en inflamación, desarrollo de tumor, y ateroesclerosis).
MX2017016530A 2015-06-22 2016-06-21 Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1). MX2017016530A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562182841P 2015-06-22 2015-06-22
US201562207531P 2015-08-20 2015-08-20
PCT/US2016/038506 WO2016209809A1 (en) 2015-06-22 2016-06-21 Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders

Publications (1)

Publication Number Publication Date
MX2017016530A true MX2017016530A (es) 2018-03-12

Family

ID=56322311

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017016530A MX2017016530A (es) 2015-06-22 2016-06-21 Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1).
MX2021007666A MX2021007666A (es) 2015-06-22 2017-12-15 Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto 1) para ser utilizada en trastornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021007666A MX2021007666A (es) 2015-06-22 2017-12-15 Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto 1) para ser utilizada en trastornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1).

Country Status (21)

Country Link
US (5) US10301262B2 (es)
EP (2) EP3939965A1 (es)
JP (3) JP6838744B2 (es)
KR (2) KR102603199B1 (es)
CN (1) CN108349891B (es)
AU (4) AU2016284162A1 (es)
BR (1) BR112017027656B1 (es)
CA (1) CA3002551A1 (es)
DK (1) DK3310760T3 (es)
EA (1) EA201890096A1 (es)
ES (1) ES2929526T3 (es)
HK (1) HK1253714A1 (es)
HU (1) HUE060476T2 (es)
IL (2) IL285890B (es)
MA (1) MA42807A (es)
MX (2) MX2017016530A (es)
NZ (1) NZ738862A (es)
PL (1) PL3310760T3 (es)
PT (1) PT3310760T (es)
SI (1) SI3310760T1 (es)
WO (1) WO2016209809A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2937386T3 (es) 2010-01-27 2023-03-28 Arena Pharm Inc Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo
EP3242666A1 (en) 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
JP6838744B2 (ja) * 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
WO2018231745A1 (en) 2017-06-14 2018-12-20 Trevena, Inc. Compounds for modulating s1p1 activity and methods of using the same
US20210386706A1 (en) * 2018-10-03 2021-12-16 Arena Pharmaceuticals, Inc. Methods for the treatment of scleroderma
CN109678715B (zh) * 2018-11-28 2019-11-12 中国药科大学 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US11884655B2 (en) 2019-11-19 2024-01-30 Trevena, Inc. Compounds and methods of preparing compounds S1P1 modulators

Family Cites Families (518)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH389134A (de) 1960-03-15 1965-03-15 Ciba Geigy Verfahren zur Herstellung neuer Anthrachinonküpenfarbstoffe
NL293572A (es) 1962-06-07
CH499528A (de) 1965-10-22 1970-11-30 Ciba Geigy Ag Verfahren zur Herstellung neuer Pyrimidine
CH480410A (de) 1967-01-09 1969-10-31 Geigy Ag J R Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen
CA961052A (en) 1967-01-12 1975-01-14 Max Schellenbaum N-2-ethylhexyl-n'-aryl ureas and preparation containing them
FR1593586A (es) 1967-10-17 1970-06-01
US3608087A (en) 1968-06-21 1971-09-21 Merck & Co Inc Feed compositions
US3887329A (en) 1969-05-05 1975-06-03 Ciba Geigy Ag Hexamethyl phosphotriamide-dye compositions
BE756953A (fr) 1969-10-02 1971-04-01 Merck & Co Inc Potentialisation d'antibiotiques
US3686238A (en) 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3852434A (en) 1970-09-11 1974-12-03 Merck & Co Inc Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
US3966744A (en) 1971-01-11 1976-06-29 Syva Company Spin labeled compounds
US3690834A (en) 1971-01-11 1972-09-12 Syva Co Ligand determination with spin labeled compounds by receptor displacement
DE2106585A1 (de) 1971-02-11 1972-08-24 Farbenfabriken Bayer Ag, 5090 Leverkusen Aminothiodiazole und Thiodiazol-Azofarbstoffe
CH558137A (de) 1971-05-17 1975-01-31 Ciba Geigy Ag Mittel zur beeinflussung des pflanzenwachstums.
CH560197A5 (en) 1971-05-17 1975-03-27 Ciba Geigy Ag 2-alkylthio-4,6-bis (subst amino)-5-nitropyrimidines - - herbicides
DE2226703A1 (de) 1972-05-25 1973-12-13 Schering Ag Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung
US3966764A (en) 1972-07-10 1976-06-29 Syva Company Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs
US3849420A (en) 1972-10-20 1974-11-19 Dow Chemical Co Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines
CH574206A5 (es) 1972-11-16 1976-04-15 Ciba Geigy Ag
DE2340569C2 (de) 1973-08-10 1982-12-02 Bayer Ag, 5090 Leverkusen Azofarbstoffe
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
US4057559A (en) 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4101541A (en) 1973-12-21 1978-07-18 Ciba-Geigy Corporation 3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs
CH584739A5 (es) 1973-12-21 1977-02-15 Ciba Geigy Ag
FR2258841B1 (es) 1974-01-29 1977-11-04 Ugine Kuhlmann
AT327605B (de) 1974-05-06 1976-02-10 Ciba Geigy Ag Mittel zur hemmung des pflanzenwachstums
AU492126B2 (en) 1974-05-14 1975-11-20 Ciba-Geigy Ag Nitropyrimidine derivatives
FR2306697A1 (fr) 1975-04-10 1976-11-05 Sogeras Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
US4139705A (en) 1977-05-20 1979-02-13 The Dow Chemical Company Pyrazolopyrimidines
US4189579A (en) 1977-05-20 1980-02-19 The Dow Chemical Company Aminoalkylthiopurines
DE2731264A1 (de) 1977-07-11 1979-02-01 Boehringer Mannheim Gmbh Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen
JPS6038696B2 (ja) 1977-12-09 1985-09-02 コニカ株式会社 ハロゲン化銀カラ−写真感光材料
US4242507A (en) 1978-02-23 1980-12-30 Fujisawa Pharmaceutical Co., Ltd. Sulfonic acid esters
DE2831580C2 (de) 1978-07-18 1980-09-18 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Reagens zur Bestimmung von Glycerin
DE2831850A1 (de) 1978-07-20 1980-02-07 Basf Ag N-arylsulfonylpyrrole, ihre herstellung und diese enthaltende therapeutische mittel
DE2906603A1 (de) 1979-02-21 1980-09-04 Boehringer Mannheim Gmbh N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel
US4343804A (en) 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
EP0050671B1 (en) 1980-04-28 1985-03-20 Teijin Limited Thiazolo(3,2-a)pyrimidine derivatives, process for preparing same, and drug containing same
EP0053678A1 (de) 1980-12-05 1982-06-16 BASF Aktiengesellschaft 5-Amino-1-phenyl-4-cyanpyrazole, diese enthaltende herbizide Mittel, Verfahren zu ihrer Herstellung und ihre Anwendung als Herbizide
RU938559C (ru) 1980-12-12 1993-11-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе S-Производные 5-амино-6-меркаптопиримидина, обладающие противоопухолевым и цитостатическим действием
DOP1981004033A (es) 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
US4476248A (en) 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
DE3334455A1 (de) 1983-03-04 1984-09-06 Bayer Ag, 5090 Leverkusen Guanidin - derivate
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
ZA848275B (en) 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
DE3406329A1 (de) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
JPS6157587A (ja) 1984-08-29 1986-03-24 Shionogi & Co Ltd 縮合複素環誘導体および抗潰瘍剤
PH22302A (en) 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
ZA861446B (en) 1985-03-01 1986-10-29 Duphar Int Res Benzoyl urea derivatives having anti-tumor activity
DE3601196A1 (de) 1986-01-17 1987-07-23 Merck Patent Gmbh 1,4-dihydropyridine
US4810699A (en) 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
CA1340284C (en) 1987-03-19 1998-12-22 Zeneca Inc. Herbicidal substituted cyclic diones
DE68926687T2 (de) 1988-01-11 1997-03-06 Fuji Photo Film Co Ltd Verfahren zur Erzeugung von extrem hochkontrastreichen negativen Bildern
US4782076A (en) 1988-03-01 1988-11-01 American Home Products Corporation Substituted 2,3,4,9-tetrahydro-1H-carbazole-1-acetic acid derivatives, composition and use
PT95692A (pt) 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
NZ238863A (en) 1990-07-19 1993-03-26 Janssen Pharmaceutica Nv Substituted thiazolyl and pyridinyl derivatives
US5221678A (en) 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
EP0567643A4 (en) 1991-01-16 1995-07-19 Yoshitomi Pharmaceutical PYRIDINE COMPOUND USED AS A SELECTIVE DRUG AND NEW PYRIDINE COMPOUND.
CA2070978A1 (en) 1991-06-11 1992-12-12 William J. Greenlee Cyclic renin inhibitors
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
JPH0533359A (ja) 1991-08-02 1993-02-09 Kubota Corp 全旋回型の小型バツクホウ
EP0556889A1 (en) 1992-02-18 1993-08-25 Duphar International Research B.V Method of preparing aryl(homo)piperazines
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
TW237456B (es) 1992-04-09 1995-01-01 Ciba Geigy
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
NZ314207A (en) 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
DE4241632A1 (de) 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
US5998499A (en) 1994-03-25 1999-12-07 Dentsply G.M.B.H. Liquid crystalline (meth)acrylate compounds, composition and method
JPH0753546A (ja) 1993-08-09 1995-02-28 Kuraray Co Ltd ジアリール置換複素環化合物およびその医薬用途
PL313973A1 (en) 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
GB9400889D0 (en) 1994-01-18 1994-03-16 Sandoz Ltd Novel compounds
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US5945426A (en) 1994-09-09 1999-08-31 Nippon Shinyaku Co., Ltd. Derivatives of pyrimidine for treating acute cerebrovascular disorders
CN1070477C (zh) 1994-11-29 2001-09-05 大日本制药株式会社 吲哚衍生物
CA2214685C (en) 1995-03-10 2008-05-20 Berlex Laboratories, Inc. Benzamidine derivatives their preparation and their use as anti-coagulants
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996033994A1 (fr) 1995-04-28 1996-10-31 Nippon Soda Co., Ltd. Derives amino-substitues, leur procede de preparation et herbicide
AU716993B2 (en) 1995-05-12 2000-03-16 Neurogen Corporation Novel deazapurine derivatives; a new class of CRF1 specific ligands
WO1996036613A1 (fr) 1995-05-19 1996-11-21 Nippon Soda Co., Ltd. Derives d'acides benzoiques substitues, procede de production desdits derives et herbicides
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
KR0169813B1 (ko) 1995-07-12 1999-01-15 김종인 4-아미노-3-아실나프티리딘 유도체
DK0852580T3 (da) 1995-08-31 2000-11-20 Lonza Ag Fremgangsmåde til fremstilling af dihydroxypyrimidin-derivater
KR100483635B1 (ko) 1995-10-26 2005-12-21 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 β3작동약으로서유용한페닐에탄올아민화합물,그의제법및그의제조에서의중간체
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
USH2007H1 (en) 1996-01-19 2001-12-04 Fmc Corporation Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines
DE19602095A1 (de) 1996-01-22 1997-07-24 Bayer Ag Halogenpyrimidine
WO1997028137A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
WO1997029109A1 (en) 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as crf receptor antagonists
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5830911A (en) 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
CZ68199A3 (cs) 1996-08-28 1999-11-17 Pfizer Inc. 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob
US6008234A (en) 1996-09-12 1999-12-28 Berlex Laboratories, Inc. Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
KR20000036017A (ko) 1996-09-12 2000-06-26 에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만 시클릭 아미노산 및 시클릭 히드록시산 유도체로 치환된 벤즈아
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
IL123232A0 (en) 1997-02-11 1999-11-30 Lilly Co Eli Medicament for inhibiting glucose metabolism deterioration
EP0970082A2 (en) 1997-02-18 2000-01-12 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
US6482836B1 (en) 1997-04-22 2002-11-19 Charles Huang CRF antagonistic quino- and quinazolines
JP2002501493A (ja) 1997-04-22 2002-01-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｒｆアンタゴニストのチオフェノピリジン類
JPH11193277A (ja) 1997-05-14 1999-07-21 Nippon Soda Co Ltd ピリミジン誘導体、その製法および有害生物防除剤
BR9811939A (pt) 1997-08-14 2000-09-05 Bayer Ag Metoximinometiloxadiazinas como pesticidas
DE19737723A1 (de) 1997-08-14 1999-02-18 Bayer Ag Methoximinomethyloxadiazine
NL1010018C2 (nl) 1997-09-09 1999-03-10 Duphar Int Res Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6861448B2 (en) 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CA2326383A1 (en) 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
EP1105394A1 (en) 1998-08-21 2001-06-13 Du Pont Pharmaceuticals Company ISOXAZOLO 4,5-d]PYRIMIDINES AS CRF ANTAGONISTS
BRPI9915552B8 (pt) 1998-11-10 2021-05-25 Janssen Pharmaceutica Nv pirimidinas inibidoras da reprodução do hiv
US6262088B1 (en) 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
ES2289610T3 (es) 1998-11-20 2008-02-01 Arena Pharmaceuticals, Inc. Receptor acoplado a proteina g humano huerfano rup3.
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
EP1140831A1 (en) 1998-12-17 2001-10-10 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine urea derivatives having 5ht1a receptor activity
US6239126B1 (en) 1998-12-17 2001-05-29 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
CZ20012006A3 (cs) 1998-12-18 2002-03-13 Axys Pharmaceuticals, Inc. Sloučenina a farmaceutický prostředek
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
KR100757282B1 (ko) 1999-03-17 2007-09-11 아스트라제네카 아베 아미드 유도체
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
EP1195165A4 (en) 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
EP1074549B1 (en) 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
SK3812002A3 (en) 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
SK285240B6 (sk) 1999-09-24 2006-09-07 Janssen Pharmaceutica N. V. Antivírusové prostriedky
AU7737900A (en) 1999-09-30 2001-04-30 Neurogen Corporation Amino substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines
YU23802A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Određeni alkilen diamin-supstituisani pirazolo/1,5-a/-1,5- piramidini i pirazolo/1,5-a/1,3,5-triazini
EA200200424A1 (ru) 1999-09-30 2002-12-26 Ньюроджен Корпорейшн Некоторые гетероциклы, замещенные алкилендиамином
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
IL139197A0 (en) 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
GR990100388A (el) 1999-11-09 2001-07-31 Φαρμακευτικος συνδυασμος αποτελουμενος απο χωριστες δοσολογικες μορφες σε συσκευασια συμμορφωσης (compliance package) ενος αναστολεα της αναγωγασης του υδροξυ-μεθυλο-γλουταρυλο συνενζυμου α (στατινης, statin) και ενος παραγωγου του φιμπρικου οξεος....
WO2001046204A1 (en) 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors
DE19962936A1 (de) 1999-12-24 2001-06-28 Bayer Ag Neue beta-Aminosäureverbindungen als Integrinantagonisten
ATE261958T1 (de) 1999-12-30 2004-04-15 Lundbeck & Co As H Phenylpiperazinyl-derivate
HUP0204272A3 (en) 2000-01-18 2005-03-29 Pfizer Prod Inc Corticotropin releasing factor antagonists, pharmaceutical compositions containing them and their use
HUP0204474A3 (en) 2000-02-09 2004-07-28 Hokuriku Pharmaceutical 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use
JP2003523418A (ja) 2000-02-15 2003-08-05 フオスター・ミラー・インコーポレイテツド 揮発性有機成分を含まない放射硬化性樹脂組成物
CA2400021A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
BR0108611A (pt) 2000-02-25 2003-05-06 Hoffmann La Roche Moduladores de receptor de adenosina
AR032152A1 (es) 2000-04-12 2003-10-29 Novartis Ag Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica
DK1282607T3 (en) 2000-05-08 2016-02-01 Janssen Pharmaceutica Nv Prodrugs of HIV replication inhibiting pyrimidines
DE10024319A1 (de) 2000-05-17 2001-11-22 Merck Patent Gmbh Bisacylguanidine
ES2278755T3 (es) 2000-05-18 2007-08-16 Bayer Healthcare Ag Regulacion del receptor acoplado a proteinas g de tipo dopamina humano.
US6440960B1 (en) 2000-05-18 2002-08-27 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
YU89002A (sh) 2000-05-25 2006-01-16 F. Hoffmann-La Roche Ag. Supstituisani 1-aminoalkil-laktami i njihova primena kao antagonista za muskarinske receptore
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2002000216A1 (en) 2000-06-28 2002-01-03 Teva Pharmaceutical Industries Ltd. Carvedilol
NZ523445A (en) 2000-06-29 2004-10-29 Abbott Lab Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
AR028782A1 (es) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
MXPA03000436A (es) 2000-07-18 2003-06-24 Yamanouchi Pharma Co Ltd Medicamentos que compreden derivados de dicianopiridina.
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
ATE362468T1 (de) 2000-07-25 2007-06-15 Merck & Co Inc N-substituierte indole mit anwendung in der behandlung von diabetes
AU2001284417A1 (en) 2000-09-05 2002-03-22 Taisho Pharmaceutical Co. Ltd. Hair growth stimulants
AU6294501A (en) 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
AU2002223626A1 (en) 2000-10-20 2002-04-29 Novartis Ag Combinations of a thyromimetic compound and a statin
CZ20031125A3 (cs) 2000-10-23 2003-10-15 Smithkline Beecham Corporation Nové sloučeniny
AU2002248221B2 (en) 2000-10-31 2006-08-17 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
JP2004529075A (ja) 2000-11-03 2004-09-24 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれに関する方法
US20020058026A1 (en) 2000-11-13 2002-05-16 Milton Hammerly HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10
WO2002039987A2 (en) 2000-11-14 2002-05-23 Neurosearch A/S Use of malaria parasite anion channel blockers for treating malaria
US7022725B2 (en) 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
UA77165C2 (en) 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
IL155702A0 (en) 2000-11-20 2003-11-23 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor
AU2002218509A1 (en) 2000-12-01 2002-06-11 Yamanouchi Pharmaceutical Co..Ltd. Method of screening remedy for diabetes
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US20020107262A1 (en) 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
DE60117605T2 (de) 2000-12-21 2006-12-07 Bristol-Myers Squibb Co. Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
ATE331512T1 (de) 2001-01-26 2006-07-15 Schering Corp Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
JP2004529100A (ja) 2001-01-30 2004-09-24 ユニバーシティ オブ バージニア パテント ファウンデーション スフィンゴシン−１−ホスフェートレセプターのアゴニストおよびアンタゴニスト
EP1357908A4 (en) 2001-01-30 2009-07-15 Merck & Co Inc ACYL-SULFAMIDES FOR THE TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS
WO2002098878A1 (en) 2001-02-08 2002-12-12 Memory Pharmaceuticals Corporation Trifluoromethylpurines as phosphodiesterase 4 inhibitors
AU2002251978B2 (en) 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
WO2002072101A1 (en) 2001-03-13 2002-09-19 Bristol-Myers Squibb Pharma Company A corticotropin releasing factor receptor ligand, its enantiomer and pharmaceutically acceptable salts
WO2002079131A1 (fr) 2001-03-29 2002-10-10 Kansai Research Institute, Inc. Compose optiquement actif et composition de resine photosensible
WO2002081454A1 (en) 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
CA2444095A1 (en) 2001-04-20 2002-10-31 Wyeth Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
ATE416762T1 (de) 2001-05-10 2008-12-15 Ono Pharmaceutical Co Carbonsäurederivate und diese als wirkstoff enthaltende arzneimittel
AU2002319183B2 (en) 2001-06-01 2007-05-10 F. Hoffmann-La Roche Ag Pyrimidine, triazine and pyrazine derivatives as glutamate receptors
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
CA2451128A1 (en) 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003026661A1 (fr) 2001-09-14 2003-04-03 Yamanouchi Pharmaceutical Co., Ltd. Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
MXPA04002679A (es) 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
EP1438048A1 (en) 2001-10-18 2004-07-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
EP1461069A2 (en) 2001-12-29 2004-09-29 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
US20050043315A1 (en) 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
US20070225351A1 (en) 2002-01-11 2007-09-27 Lippa Arnold S Methods and compositions for controlling body weight and appetite
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
EP1469863A2 (en) 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
US20050239899A1 (en) 2002-01-18 2005-10-27 Wolfgang Fecke Beta-secretase inhibitors
GB0201850D0 (en) 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
AU2003218056A1 (en) 2002-03-01 2003-09-16 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
CA2477423A1 (en) 2002-03-01 2003-09-12 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
AU2003228283A1 (en) 2002-03-07 2003-09-22 X-Ceptor Therapeutics, Inc. Quinazolinone modulators of nuclear receptors
WO2003077656A1 (en) 2002-03-15 2003-09-25 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
AR039090A1 (es) 2002-03-22 2005-02-09 Novartis Ag Combinacion de compuestos organicos
AU2003225027A1 (en) 2002-04-16 2003-11-03 Merck And Co., Inc. Combination therapy using a ppar alpha/gamma agonist
US7544675B2 (en) 2002-04-18 2009-06-09 Ucb, S.A. Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
WO2003103640A1 (en) 2002-06-10 2003-12-18 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (“statins”), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
CA2488617A1 (en) 2002-06-10 2003-12-18 Eugene R. Cooper Nanoparticulate sterol formulations and sterol combinations
US7763278B2 (en) 2002-06-10 2010-07-27 Elan Pharma International Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
US20060122106A1 (en) 2002-06-14 2006-06-08 Amylin Pharmaceuticals, Inc Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
DE10226943A1 (de) 2002-06-17 2004-01-08 Bayer Ag Phenylaminopyrimidine und ihre Verwendung
CA2488117A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
GB0214254D0 (en) 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201976D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
EP1531832B1 (en) 2002-06-28 2009-04-15 Glykos Finland Oy Therapeutic compositions for use in prophylaxis or treatment of diarrheas
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
JPWO2004007472A1 (ja) 2002-07-10 2005-11-17 小野薬品工業株式会社 Ｃｃｒ４アンタゴニストおよびその医薬用途
AU2003261204A1 (en) 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
JP2006501200A (ja) 2002-07-23 2006-01-12 スミスクライン ビーチャム コーポレーション キナーゼインヒビターとしてのピラゾロピリミジン
WO2004009596A2 (en) 2002-07-23 2004-01-29 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
WO2004013633A2 (en) 2002-07-29 2004-02-12 Axxima Pharmaceuticals Ag Method for isolating atp binding proteins by means of immobolized protein inhibitors
AU2003256911B2 (en) 2002-07-30 2008-07-10 Merck Sharp & Dohme Corp. PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
EP1546110A4 (en) 2002-07-30 2008-03-26 Univ Virginia ACTIVE COMPOUNDS IN THE SIGNALING OF SPHINGOSINE 1-PHOSPHATE
JP4475406B2 (ja) 2002-07-30 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション 異常脂血症および他の脂質障害の治療用のＰＰＡＲα選択的化合物
JP2004067575A (ja) 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
WO2004014871A1 (en) 2002-08-08 2004-02-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
WO2004017896A2 (en) 2002-08-21 2004-03-04 Merck & Co., Inc. Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
US7393960B2 (en) 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
ES2342596T3 (es) 2002-08-29 2010-07-09 MERCK SHARP & DOHME CORP. Indoles con actividad anti-diabetica.
US20050191612A1 (en) 2002-09-11 2005-09-01 Takahide Ohishi Method of screening insulin content enhancer
AU2003275242B2 (en) 2002-09-27 2010-03-04 Merck Sharp & Dohme Corp. Substituted pyrimidines
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
AU2003282679A1 (en) 2002-10-04 2004-05-04 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
AU2003284111A1 (en) 2002-10-09 2004-05-04 Genaissance Pharmaceuticals, Inc. Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol
WO2004035588A1 (en) 2002-10-15 2004-04-29 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
CA2503715A1 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US20040110241A1 (en) 2002-12-06 2004-06-10 Segal Mark S. Materials and methods for monitoring vascular endothelial function
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004058174A2 (en) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
AU2003297232B2 (en) 2002-12-20 2010-02-04 Merck Sharp & Dohme Corp. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
GB0230020D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
GB0230021D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
DK1599468T3 (da) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
EP1583531B1 (en) 2003-01-16 2007-04-18 SB Pharmco Puerto Rico Inc Heteroaryl-substituted pyrrolo[2, 3- b]pyridine derivatives as crf receptor antagonists
US7319170B2 (en) 2003-01-17 2008-01-15 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzensulfonmide derivatives
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
AU2004210697B2 (en) 2003-02-11 2007-10-18 Irm Llc Novel bicyclic compounds and compositions
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
KR101005171B1 (ko) 2003-02-18 2011-01-04 교린 세이야꾸 가부시키 가이샤 아미노포스폰산 유도체와 그 부가염 및 ｓ1ｐ 수용체조절제
CN1751038A (zh) 2003-02-24 2006-03-22 艾尼纳制药公司 作为葡萄糖代谢调节剂的经取代芳基和杂芳基衍生物及葡萄糖代谢失调的预防和治疗
JP2004269469A (ja) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd ピリミジン誘導体又はその塩
JP2004269468A (ja) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd ピリミジン誘導体又はその塩
BRPI0408897A (pt) 2003-03-28 2006-04-18 Pfizer Prod Inc derivados de 1,2,3,4-tetrahidro-e 1,2-dihidro-quinolina 1,2,4-substituìdos como inibidores de cetp para o tratamento de arteroesclerose e obesidade
ES2383298T3 (es) 2003-04-30 2012-06-20 Novartis Ag Derivados del amino-propanol como moduladores del receptor esfingosina-1-fosfato
CA2523677A1 (en) 2003-04-30 2004-11-11 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
MXPA05011539A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b.
TWI494102B (zh) 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
EP1475094B8 (en) 2003-05-06 2011-01-12 Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO) Pyrazolo[4,3-D]pyrimidines, process for their preparation and methods of use
SE0301368D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
US20060252741A1 (en) 2003-05-15 2006-11-09 Colandrea Vincent J 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2004104205A2 (en) 2003-05-16 2004-12-02 Merck & Co., Inc. Enzymatic preparation of chiral indole esters
JP4728962B2 (ja) 2003-05-19 2011-07-20 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
EP1638551B1 (en) 2003-05-19 2011-12-21 Irm Llc Immunosuppressant compounds and compositions
CA2524048C (en) 2003-05-19 2013-06-25 Irm Llc Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
WO2004110368A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
AU2003902882A0 (en) 2003-06-10 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Piperidyl derivatives
GB0313612D0 (en) 2003-06-12 2003-07-16 Novartis Ag Organic compounds
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP2287166A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
JPWO2005012221A1 (ja) 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
MY147449A (en) 2003-08-15 2012-12-14 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
WO2005021503A1 (en) 2003-08-28 2005-03-10 Novartis Ag Aminopropanol derivatives
CN101407471A (zh) 2003-08-29 2009-04-15 小野药品工业株式会社 能够结合s1p受体的化合物及其药物用途
AU2004268024B2 (en) 2003-09-02 2007-07-12 Merck Sharp & Dohme Llc Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
WO2005023762A1 (en) 2003-09-04 2005-03-17 Abbott Laboratories Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
WO2005023771A1 (ja) 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
TW201127828A (en) 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20050065144A1 (en) 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005025554A2 (en) 2003-09-09 2005-03-24 Japan Tobacco Inc. Dipeptidyl peptidase iv inhibitor
JP4722851B2 (ja) 2003-09-23 2011-07-13 メルク・シャープ・エンド・ドーム・コーポレイション キノリンカリウムチャネル阻害剤
WO2005030127A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
CN1859908A (zh) 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
WO2005033099A2 (en) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US20060089335A1 (en) 2003-10-14 2006-04-27 Guosong Liu Compositions and methods for enhancing cognitive function and synaptic plasticity
GB0324236D0 (en) 2003-10-16 2003-11-19 Astrazeneca Ab Chemical compounds
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
AU2004289304A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
WO2005044780A1 (ja) 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
WO2005047297A1 (en) 2003-11-12 2005-05-26 Phenomix Corporation Heterocyclic boronic acid compounds
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005058315A1 (en) 2003-12-12 2005-06-30 Ribapharm, Inc. Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity
WO2005058849A1 (en) 2003-12-15 2005-06-30 Glenmark Pharmaceuticals Ltd. New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them
JP4773972B2 (ja) 2003-12-17 2011-09-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｓ１Ｐ（Ｅｄｇ）受容体作働薬としての（３，４−ジ置換）プロパンカルボン酸
JP4766384B2 (ja) 2003-12-19 2011-09-07 小野薬品工業株式会社 リゾホスファチジン酸受容体拮抗作用を有する化合物およびその用途
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
EP1711491A1 (en) 2003-12-24 2006-10-18 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
WO2005072530A1 (en) 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005075426A1 (en) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US7534798B2 (en) 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
KR20110136901A (ko) 2004-02-24 2011-12-21 상꾜 가부시키가이샤 아미노 알코올 화합물
JP4740884B2 (ja) 2004-02-24 2011-08-03 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制性化合物および組成物
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
AU2005219791B2 (en) 2004-03-05 2011-06-09 Msd K.K. Diaryl-substituted five-membered heterocycle derivative
GB0405289D0 (en) 2004-03-09 2004-04-21 Novartis Ag Organic compounds
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
JP5239071B2 (ja) 2004-04-02 2013-07-17 メルク・シャープ・アンド・ドーム・コーポレーション シクロアルカノインドール誘導体の調製のために有用な非対称水素化方法
MXPA06011799A (es) 2004-04-12 2006-12-15 Sankyo Co Derivados de tienopiridina.
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
DK1756084T3 (da) 2004-06-04 2009-03-23 Arena Pharm Inc Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
PL1772145T3 (pl) 2004-07-16 2011-08-31 Kyorin Seiyaku Kk Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
TW200611687A (en) 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
CN1993333B (zh) 2004-08-04 2012-08-01 大正制药株式会社 三唑衍生物
WO2006020951A1 (en) 2004-08-13 2006-02-23 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
US20060223866A1 (en) 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
US20080167321A1 (en) 2004-09-20 2008-07-10 Xenon Pharmaceuticals Inc. Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase
US7250441B2 (en) 2004-09-23 2007-07-31 Wyeth Carbazole and cyclopentaindole derivatives to treat infection with Hepatitis C virus
ATE481969T1 (de) 2004-10-01 2010-10-15 Merck Sharp & Dohme Aminopiperidine als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
US7557112B2 (en) 2004-10-08 2009-07-07 Astellas Pharma Inc. Aromatic-ring-fused pyrimidine derivative
MX2007004262A (es) 2004-10-12 2008-03-04 Forbes Medi Tech Res Inc Compuestos y metodos para tratar resistencia a la insulina y cardiomiopatia.
TW200621257A (en) 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
DK1650186T3 (da) 2004-10-22 2008-10-13 Sun Pharmaceutical Ind Ltd Nye dicarboxylsyrederivater
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
US20080312277A1 (en) 2004-11-03 2008-12-18 Leonard James N Gpr41 and Modulators Thereof for the Treatment of Insulin-Related Disorders
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
JP2008520692A (ja) 2004-11-18 2008-06-19 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 複素環置換カルボン酸
WO2006057448A1 (ja) 2004-11-26 2006-06-01 Takeda Pharmaceutical Company Limited アリールアルカン酸誘導体
WO2006060808A1 (en) 2004-12-03 2006-06-08 Teva Pharmaceutical Industries Ltd. Ezetimibe polymorphs
WO2006063033A2 (en) 2004-12-06 2006-06-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
PL1826197T3 (pl) 2004-12-13 2012-06-29 Ono Pharmaceutical Co Pochodna kwasu aminokarboksylowego i jej zastosowanie lecznicze
WO2006064744A1 (ja) 2004-12-13 2006-06-22 Daiichi Sankyo Company, Limited 糖尿病の治療のための医薬組成物
US8193359B2 (en) 2004-12-24 2012-06-05 Prosidion Limited G-protein coupled receptor agonists
US20080312281A1 (en) 2004-12-24 2008-12-18 Matthew Colin Thor Fyfe G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
DOP2006000009A (es) 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
US20080124384A1 (en) 2005-01-19 2008-05-29 Blum Charles A Heteroaryl Substituted Piperazinyl-Pyridine Analogues
JP5798282B2 (ja) 2005-01-25 2015-10-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ メソゲン性化合物、液晶媒体および液晶ディスプレイ
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
MX2007009848A (es) 2005-02-14 2008-03-10 Univ Virginia Agonistas de esfingosina 1-fosfato comprendiendo cicloalcanos y heterociclos de 5 miembros substituidos por grupos amino y fenilo.
CN101180050B (zh) 2005-03-23 2011-07-27 埃科特莱茵药品有限公司 作为鞘氨醇-1-磷酸盐-1受体激动剂的新颖噻吩衍生物
JP5047941B2 (ja) 2005-03-23 2012-10-10 アクテリオン ファーマシューティカルズ リミテッド 免疫調節物質としての水素付加されたベンゾ（ｃ）チオフェン誘導体
RU2404178C2 (ru) 2005-03-23 2010-11-20 Актелион Фармасьютиклз Лтд Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1
AU2006256968A1 (en) 2005-06-08 2006-12-14 Novartis Ag Polycyclic oxadiazoles or I soxazoles and their use as SIP receptor ligands
US20090105136A1 (en) 2005-06-09 2009-04-23 Jun Suzuki NPY Y2 Agonist for Use as Therapeutic Agent for Disease Accompanied by Diarrhea
TWI418350B (zh) 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
AU2006260573A1 (en) 2005-06-24 2006-12-28 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives
MX2007016545A (es) 2005-06-30 2008-02-21 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
RU2386630C2 (ru) 2005-07-01 2010-04-20 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинтирозинкиназы
US20070060573A1 (en) 2005-08-10 2007-03-15 Lars Wortmann Acyltryptophanols
AU2006283175A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
CN101263135A (zh) 2005-09-16 2008-09-10 艾尼纳制药公司 代谢调节剂和代谢相关病症的治疗
TW200745055A (en) 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
WO2007037196A1 (ja) 2005-09-29 2007-04-05 Yamamoto Chemicals, Inc. インドリン系化合物及びその製造方法
PT1932522E (pt) 2005-10-07 2012-06-26 Kyorin Seiyaku Kk Agente terapêutico para doenças do fígado contendo, como princípio activo, um derivado de 2- amino-1,3-propanodiol
AU2006317689B2 (en) 2005-11-23 2013-07-25 Epix Delaware, Inc. S1P receptor modulating compounds and use thereof
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
BRPI0620756B1 (pt) 2005-12-29 2021-06-01 Tersera Therapeutics Llc Derivados de aminoácido multicíclicos, formulação farmacêutica compreendendo os mesmos e seus usos para inibir a atividade de triptofano hidroxilase 1 (tph1)
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
TW200736234A (en) 2006-01-17 2007-10-01 Astrazeneca Ab Chemical compounds
ES2600804T3 (es) 2006-01-19 2017-02-10 Orchid Pharma Limited Nuevos heterociclos
EP1979345B1 (en) 2006-01-24 2009-11-04 Actelion Pharmaceuticals Ltd. Novel pyridine derivatives
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CA2641718A1 (en) 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
TW200806611A (en) 2006-02-09 2008-02-01 Daiichi Seiyaku Co Novel amidopropionic acid derivatives and medicine containing the same
US20070191371A1 (en) 2006-02-14 2007-08-16 Kalypsys, Inc. Heterocyclic modulators of ppar
CN101460458A (zh) 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
WO2007095561A2 (en) 2006-02-15 2007-08-23 Allergan, Inc. Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
EP1991535A1 (en) 2006-02-21 2008-11-19 University Of Virginia Patent Foundation Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as sip receptor agonists
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
CA2646430A1 (en) 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
CA2646469A1 (en) 2006-03-21 2007-09-27 Epix Delaware, Inc. S1p receptor modulating compounds
JP2007262009A (ja) 2006-03-29 2007-10-11 Dai Ichi Seiyaku Co Ltd ヘテロアリール低級カルボン酸誘導体
ES2453372T3 (es) 2006-04-03 2014-04-07 Astellas Pharma Inc. Derivados de oxadiazol como agonistas de S1P1
CL2007001011A1 (es) 2006-04-11 2008-05-16 Arena Pharm Inc Metodo para la identificacion de secretagogos de gip, polipeptido inhibidor gastrico; y uso de un receptor acoplado a proteina g para clasificar compuestos de prueba como secretagogos de gip.
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
GB0607389D0 (en) 2006-04-12 2006-05-24 Novartis Ag Organic compounds
WO2007129473A1 (ja) 2006-05-09 2007-11-15 Daiichi Sankyo Company, Limited 二環性アリール誘導体
US20090324581A1 (en) 2006-05-09 2009-12-31 Daiichi Sankyo Company Limited Heteroarylamide lower carboxylic acid derivative
WO2007132307A1 (en) 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
TW200811140A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
WO2008008887A2 (en) 2006-07-13 2008-01-17 Smithkline Beecham Corporation Gpr119 agonists for treating metabolic disorders
AR062156A1 (es) 2006-08-01 2008-10-22 Praecis Pharm Inc Compuestos agonistas y selectivos del receptor s1p-1
JP2009545597A (ja) 2006-08-01 2009-12-24 プリーシス・ファーマシューティカルズ・インコーポレイテッド スフィンゴシン−１−ホスフェート受容体（ｓｌｐ）のアゴニスト
JP2009545630A (ja) 2006-08-04 2009-12-24 プリーシス・ファーマシューティカルズ・インコーポレイテッド 化合物
NZ574011A (en) 2006-08-08 2011-10-28 Kyorin Seiyaku Kk Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
WO2008024196A1 (en) 2006-08-24 2008-02-28 Praecis Pharmaceuticals Incorporated Chemical compounds
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
WO2008025799A1 (en) 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyridazine compounds for treating gpr119 related disorders
BRPI0716815A2 (pt) 2006-09-07 2013-11-05 Allergan Inc Co posto heteroatomáticos tendo atividade biológia agonista e/ou antagonista de receptor de esfinfosina-1-fosfato (s1p)
AR061841A1 (es) 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
AU2007292993B2 (en) 2006-09-07 2013-01-24 Idorsia Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents
CN101511783A (zh) 2006-09-08 2009-08-19 诺瓦提斯公司 用于治疗淋巴细胞相互作用介导的疾病的n-联芳(杂)芳基磺酰胺衍生物
RU2442780C2 (ru) 2006-09-21 2012-02-20 Актелион Фармасьютиклз Лтд Фенильные производные и их применение в качестве иммуномодуляторов
CN101657471B (zh) 2006-12-06 2013-07-03 史密丝克莱恩比彻姆公司 二环化合物及其作为抗糖尿病药的用途
EP2112880A4 (en) 2006-12-14 2011-12-21 Merck Sharp & Dohme ACYL-BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND PROCESSING METHODS
AU2007334436A1 (en) 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
TW200838497A (en) 2006-12-21 2008-10-01 Abbott Lab Sphingosine-1-phosphate receptor agonist and antagonist compounds
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
KR20090101307A (ko) 2007-01-11 2009-09-24 알러간, 인코포레이티드 스핑고신-1-포스페이트(ｓ1ｐ) 수용체 길항제 생물학적 활성을 갖는 6-치환된 인돌-3-카르복실산 아미드 화합물
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
WO2008097819A2 (en) 2007-02-05 2008-08-14 Smithkline Beecham Corporation Chemical compounds
DK2125797T3 (da) 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
EP2121648A2 (en) 2007-03-21 2009-11-25 EPIX Pharmaceuticals, Inc. S1p receptor modulating compounds and use thereof
WO2008128832A1 (en) 2007-04-18 2008-10-30 Nicox S.A. Nitroderivatives of non-peptidic renin inhibitors for the treatment of cardiovascular, renal and chronic liver disease, inflammations and metabolic syndrome
KR20090130062A (ko) 2007-04-19 2009-12-17 글락소 그룹 리미티드 스핑고신 １―포스페이트 (ｓ１ｐ) 효능제로서 사용하기 위한 옥사디아졸 치환된 인다졸 유도체
PE20090222A1 (es) 2007-05-04 2009-03-27 Bristol Myers Squibb Co Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
EP2014653A1 (en) 2007-06-15 2009-01-14 Bioprojet Novel dicarboxylic acid derivatives as S1P1 receptor agonists
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
WO2009019506A1 (en) 2007-08-03 2009-02-12 Astrazeneca Ab Heterocyclyc sulfonamides having edg-1 antagonistic activity
JP5508265B2 (ja) 2007-08-08 2014-05-28 メルク セローノ ソシエテ アノニム 多発性硬化症の治療のための、スフィンゴシン１−ホスフェート（ｓ１ｐ）受容体に結合する６−アミノ−ピリミジン−４−カルボキサミド誘導体及び関連化合物
BRPI0817211A2 (pt) 2007-09-20 2017-05-16 Irm Llc composto composições como moduladores da atividade de gpr119
TW200930368A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
US8637704B2 (en) 2007-11-28 2014-01-28 Synta Pharmaceuticals Corp. Polymorphs of N-malonyl-bis(N′-methyl-N′-thiobenzoylhydrazide)
EP2222668B1 (en) 2007-12-18 2011-11-02 Arena Pharmaceuticals, Inc. Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
AU2009206733A1 (en) 2008-01-25 2009-07-30 Arena Pharmaceuticals, Inc. Dihydro- 1H- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as S1P1 agonists
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
EP2258040A2 (en) 2008-02-28 2010-12-08 Solar Roofing Systems, Inc. Photovoltaic roofing tile with fire suppression
WO2009115954A1 (en) 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
JP2011516557A (ja) 2008-04-07 2011-05-26 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物
WO2009125434A2 (en) 2008-04-07 2009-10-15 Cadila Healthcare Limited Oxime derivatives
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
NZ589617A (en) 2008-05-14 2012-06-29 Scripps Research Inst 3-(Inden-4-yl)-5-(phenyl)-1,2,4-oxadiazole and 3-(tetralin-5-yl)-5-(phenyl)-1,2,4-oxadiazole derivatives
WO2009151626A1 (en) 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
WO2009151621A1 (en) 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
HUE030424T2 (en) 2008-07-23 2017-05-29 Arena Pharm Inc Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-ylacetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
SI2342205T1 (sl) 2008-08-27 2016-09-30 Arena Pharmaceuticals, Inc. Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj
PL2379069T3 (pl) 2008-12-22 2015-08-31 Novartis Ag Schemat dawkowania agonisty receptora S1P
SI3409274T1 (sl) 2008-12-22 2020-03-31 Novartis Ag Režim odmerjanja za S1P receptor agonist
CA2747809A1 (en) 2008-12-23 2010-07-01 Joel M. Harris Bicyclic heterocycle derivatives and methods of use thereof
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
WO2010074271A1 (ja) 2008-12-26 2010-07-01 武田薬品工業株式会社 糖尿病治療剤
JPWO2010084944A1 (ja) 2009-01-22 2012-07-19 田辺三菱製薬株式会社 新規ピロロ［２，３−ｄ］ピリミジン化合物
CA2749960A1 (en) 2009-02-10 2010-08-19 Abbott Laboratories Agonists and antagonists of the s1p5 receptor, and methods of uses thereof
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
WO2011005295A1 (en) 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
AR077638A1 (es) 2009-07-15 2011-09-14 Lilly Co Eli Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
EP2597089A1 (en) 2009-10-29 2013-05-29 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
US8299059B2 (en) 2009-10-30 2012-10-30 Eli Lilly And Company Crystalline compound and a process for its preparation
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
EP2470529B1 (en) 2009-12-30 2014-11-19 Medichem, S.A. A 1-(1h-1,2,4-triazol-1-yl)butan-2-ol derivative for pharmaceutical use, and the use of a 1-(1h-1,2,4-triazol-1-yl)butan-2-ol derivate with substantially undefined crystal shape for preparing said 1-(1h-1,2,4-triazol-1-yl)butan-2-ol derivative
ES2937386T3 (es) 2010-01-27 2023-03-28 Arena Pharm Inc Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo
WO2011109471A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
BR112012025592A2 (pt) 2010-04-06 2019-09-24 Arena Pharm Inc moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos
WO2012015758A2 (en) 2010-07-30 2012-02-02 Saint Louis University Methods of treating pain
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
BR112013019683B1 (pt) 2011-02-07 2022-04-19 Biogen Inc Compostos que modulam s1p, composição farmacêutica, e uso dos mesmos
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
BR112014018485A8 (pt) 2012-02-03 2017-07-11 Teva Pharma Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
US20160038506A1 (en) 2012-02-14 2016-02-11 Repros Therapeutics Inc. Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
US8962888B2 (en) 2012-12-03 2015-02-24 Physical Sciences, Inc. Forming spherical crystal habit
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
EP3242666A1 (en) 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
KR20210029190A (ko) 2018-06-06 2021-03-15 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
US20210386706A1 (en) 2018-10-03 2021-12-16 Arena Pharmaceuticals, Inc. Methods for the treatment of scleroderma
AU2019387212A1 (en) 2018-11-30 2021-06-24 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US20220142977A1 (en) 2019-01-08 2022-05-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Also Published As

Publication number Publication date
IL285890A (en) 2021-09-30
US20190330153A1 (en) 2019-10-31
JP2023022155A (ja) 2023-02-14
US20240140911A1 (en) 2024-05-02
JP2020196756A (ja) 2020-12-10
MX2021007666A (es) 2021-08-05
EA201890096A1 (ru) 2018-08-31
IL285890B (en) 2022-07-01
HUE060476T2 (hu) 2023-03-28
AU2021249972B2 (en) 2022-12-15
KR102603199B1 (ko) 2023-11-16
ES2929526T3 (es) 2022-11-29
US10676435B2 (en) 2020-06-09
KR20230160955A (ko) 2023-11-24
MA42807A (fr) 2018-07-25
HK1253714A1 (zh) 2019-06-28
US20180186738A1 (en) 2018-07-05
PT3310760T (pt) 2022-11-10
CN108349891A (zh) 2018-07-31
JP2018525336A (ja) 2018-09-06
WO2016209809A1 (en) 2016-12-29
AU2021249972A1 (en) 2021-11-04
CA3002551A1 (en) 2016-12-29
US20200361869A1 (en) 2020-11-19
BR112017027656A2 (pt) 2018-08-28
EP3310760A1 (en) 2018-04-25
AU2016284162A1 (en) 2018-02-01
JP6838744B2 (ja) 2021-03-03
IL256084B (en) 2021-10-31
EP3310760B1 (en) 2022-09-14
US10301262B2 (en) 2019-05-28
AU2020204164B2 (en) 2021-11-04
US11884626B2 (en) 2024-01-30
IL256084A (en) 2018-02-28
PL3310760T3 (pl) 2023-03-06
AU2020204164A1 (en) 2020-07-09
NZ738862A (en) 2023-12-22
US20220002244A1 (en) 2022-01-06
DK3310760T3 (da) 2022-10-24
AU2023200978A1 (en) 2023-03-23
US11091435B2 (en) 2021-08-17
BR112017027656B1 (pt) 2023-12-05
CN108349891B (zh) 2022-04-05
KR20180015259A (ko) 2018-02-12
SI3310760T1 (sl) 2023-02-28
EP3939965A1 (en) 2022-01-19
EP3310760B8 (en) 2022-10-19

Similar Documents

Publication Publication Date Title
MX2021007666A (es) Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto 1) para ser utilizada en trastornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1).
SG10201906876PA (en) Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
IL281708A (en) (4)-7)-2-(R-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for use in the treatment of ulcerative colitis
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
NZ722603A (en) Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MY194850A (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
PH12016502447B1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EA201700042A1 (ru) Соединения имидазопиридазина
EA201691330A1 (ru) Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазы
MY196473A (en) 7-Substituted 1-Aryl-Naphthyridine-3-Carboxylic Acid Amides and use Thereof
MX2013003202A (es) Inhibidores de oxadiazol de la produccion de leucotrienos.
WO2015079067A3 (en) Various compounds as autophagy stimulants
MX2016015577A (es) La teobromina o sus derivados para el tratamiento o la prevencion de la litiasis renal.
WO2015114660A8 (en) Novel heterobicyclic compounds as kappa opioid agonists
IN2013CH01199A (es)
EP3067422A3 (en) Ct-1 inhibitors
EA201791398A1 (ru) Производные фумагиллола
RU2014119622A (ru) Способ очистки бетулина
TN2013000122A1 (en) Oxadiazole inhibitors of leukotriene production
TN2013000052A1 (en) Oxadiazole inhibitors of leukotriene production